<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149993</url>
  </required_header>
  <id_info>
    <org_study_id>2009-496</org_study_id>
    <nct_id>NCT01149993</nct_id>
  </id_info>
  <brief_title>Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation</brief_title>
  <official_title>Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing living donor renal transplant will be asked to participate to determine
      whether pre-operative dosing of immunosuppressive medication, and the donor organ receiving
      an additional dose of antibody induction therapy helps to alleviate potential damage to the
      transplanted organ post-transplant. A number of lab tests will be done post-transplant to
      determine how well the kidney is functioning.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    FDA clinical hold, IND withdrawn.
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in ischemia reperfusion injury</measure>
    <time_frame>one year</time_frame>
    <description>Monitor immediate graft functioning, mitochodrial membrane potential, serum creatinine, and cylex immunomonitoring to determine if pre-transplant immunosuppression, and an additional intra-operative dose of induction agent helps to reduce ischemic reperfusion injury.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>secondary outcomes</measure>
    <time_frame>one year</time_frame>
    <description>incidence of acute rejection, graft survival, patient survival, change in cylex values</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Renal Transplantation</condition>
  <condition>Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>pre-transplant immunosuppression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects in this arm will receive Myfortic 720mg twice daily for 7 days prior to transplantation. Intra-operatively, the donor kidney will receive an infusion of Thymoglobulin, prior to the transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pre-transplant induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects in this arm will not receive any pre-transplant immunosuppression. However, the donor kidney will receive an infusion of Thymoglobulin prior to transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>subjects in this arm will not receive any pre-transplant immunosuppression, and the donor kidney will not receive an additional dose of Thymoglobulin prior to transplantation. This is the standard of care protocol for Georgetown University Hospital</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myfortic (mycophenolic acid)</intervention_name>
    <description>720mg twice a day for 7 days prior to transplantation</description>
    <arm_group_label>pre-transplant immunosuppression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Myfortic (mycophenolic acid)</intervention_name>
    <description>720mg twice a day after transplant</description>
    <arm_group_label>pre-transplant immunosuppression</arm_group_label>
    <arm_group_label>pre-transplant induction</arm_group_label>
    <arm_group_label>standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin (anti-thymocyte globulin)</intervention_name>
    <description>up to 25 mg will be infused into the renal artery of a donor kidney prior to transplantation into the recipient.</description>
    <arm_group_label>pre-transplant immunosuppression</arm_group_label>
    <arm_group_label>pre-transplant induction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin (anti-thymocyte globulin)</intervention_name>
    <description>standard of care for Georgetown University Hospital: 1.5 mg/kg/day infused over 6 hours.</description>
    <arm_group_label>pre-transplant immunosuppression</arm_group_label>
    <arm_group_label>pre-transplant induction</arm_group_label>
    <arm_group_label>standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be able to provide written informed consent.

          2. All recipients of a kidney from a living donor only, either a de novo transplant, or
             re-transplant

          3. All patients evaluated and listed with the United Network for Organ Sharing (UNOS) who
             are eligible to receive a kidney transplant under GUH's standard protocol.

          4. Patients between 18-80 years of age

        Exclusion Criteria:

          1. Recipients of multi-organ transplant

          2. Patients with known allergies of hypersensitivities to any of the drugs used in this
             protocol

          3. Recipients of kidneys from a deceased donor

          4. Recipients who are co-infected with Hepatitis B, Hepatitis C or HIV

          5. Women who are pregnant

          6. Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, including women whose career, lifestyle or sexual orientation
             precludes intercourse with a male partner unless they agree to avoid pregnancy
             throughout the duration of the trial and for 3 months following the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph K Melancon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2010</study_first_submitted>
  <study_first_submitted_qc>June 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2010</study_first_posted>
  <last_update_submitted>June 6, 2014</last_update_submitted>
  <last_update_submitted_qc>June 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Georgetown University</investigator_affiliation>
    <investigator_full_name>Keith Melancon,MD</investigator_full_name>
    <investigator_title>Director of kidney and pancreas transplantation</investigator_title>
  </responsible_party>
  <keyword>living donation</keyword>
  <keyword>kidney transplantation</keyword>
  <keyword>delayed graft function</keyword>
  <keyword>ischemia reperfusion injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

